- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01913171
Effect of Hula Hooping as Compared to Walking on Adipose Tissue Distribution, Metabolic Parameters and Adipose Tissue Gene Expression
Study Overview
Status
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Helsinki, Finland, FI-00290
- Department of Medicine, University of Helsinki
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- age between 18 and 70 years
- central adiposity as measured by the waist circumference (>80 cm in females and >94 cm in males) (9)
- ability to hula-hoop for a minimum of 2 minutes and to have the necessary space available for this activity either at home or at work
- ability to communicate meaningfully with the investigator and legal competence to provide written informed consent
Exclusion Criteria:
- clinical or biochemical evidence of disease other than obesity as judged by history, physical examination and standard laboratory tests
- excessive use of alcohol, i.e., over 20 g/day
- use of medications known to affect glucose or lipid metabolism and
- pregnancy or lactation
Study Plan
How is the study designed?
Design Details
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: Walking
WALK.
The participants were instructed to walk daily, at first week 12minutes/day, week II 16mins/day, week III 20mins/day, week IV 24 mins/day, week V 28mins/day, week VI 32mins/day at a pace that would moderately increase heart rate and result in sweating
|
|
|
Active Comparator: Hula-hooping
HULA.
The participants were instructed to hula hoop daily, at first week 6minutes/day, week II 8mins/day, week III 10mins/day, week IV 12 mins/day, week V 14mins/day, week VI 16mins/day
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Android obesity
Time Frame: 6weeks
|
The primary objective was to evaluate the change in the % fat in the android region as measured by DEXA during 6 weeks of HULA as compared to WALK
|
6weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
metabolic parameters
Time Frame: 6weeks
|
The secondary objectives included the comparison of differences in waist circumference (cm), relative and absolute trunk and limb muscle mass as measured by DEXA (% and kg), fasting plasma glucose (mmol/l), fasting serum insulin (mU/l), liver enzymes (U/l), fasting plasma LDL and HDL cholesterol and triglycerides (mmol/l).
Gene expression was analyzed in adipose tissue biopsies collected before and after each exercise intervention.
|
6weeks
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
adipose tissue inflammation
Time Frame: 6weeks
|
To determine the effects of HULA compared to WALK on adipose tissue inflammation, a needle aspiration biopsy of abdominal s.c. adipose tissue was taken under local anesthesia with lidocaine before and after each exercise intervention. The adipose tissue sample was immediately frozen in liquid nitrogen and then stored at -80°C until analysis. Total RNA from s.c. AT was isolated.Relative quantification for the genes of interest (see list below) was carried out using normalization to the 36B4 and β-actin mRNA values. ABCA1 Adiponectin ANGPTL8 CHOP CD4 CD8 CD68 ETFDH FOXP3 GLUT4 MCP-1 MRC-1 PGC-1α VEGF-A β-actin |
6weeks
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- HULA 233401
- HULA233401 (Other Identifier: HUS Tietu)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.